SGHT News and Press, Sight Sciences Inc. From 11/13/22

Sight Sciences, Inc. (SGHT) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor - Investor Relations, Gilmartin Group Paul Badawi - Chief Executive Officer Jesse Selnick - Chief Financial Officer Conference Call ...

Sight Sciences ( NASDAQ: SGHT ) stock gained 35% to its highest level in over four months after the medical device firm reported strong Q3 earnings and raised the lower end of its FY revenue guidance range. Sight Sciences ( SGHT ) now expects 2022 rev...

Sight Sciences press release ( NASDAQ: SGHT ): Q3 GAAP EPS of -$0.46 in-line. Revenue of $18.7M (+42.7% Y/Y) beats by $1.02M . Sight Sciences now projects revenue for the full year 2022 to range from $70 million to $72 million, which represents growth of approximat...

MENLO PARK, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended Septe...

Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery. Despite glaucoma medications and prior microbypass stenting, target IOP may no longer be achieved over time. During 3 to 42 months follow-up, the majo...

MENLO PARK, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the ...

Randomized, controlled clinical trial data on advanced dry eye patients from the OLYMPIA trial recently published in Clinical Ophthalmology Study authors concluded that the TearCare procedure delivered superior symptoms improvements over LipiFlow in patients suffering from advanced dr...

MENLO PARK, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), today announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI Surgical System as a standalone minimally invasive glaucoma surgery (MIGS) during this yearȁ...

MENLO PARK, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. announced today that its OMNI Surgical System will be featured in seven clinical presentations at the 2022 European Society of Cataract & Refractive Surgeons (ESCRS) meeting, to be held in Milan, ...

310-patient RCT designed to evaluate the superiority of TearCare® (device) vs Restasis® (drug) in patients with chronic dry eye disease is now fully enrolled 6-Month efficacy results expected by Summer 2023 MENLO PARK, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sight S...